Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tallikut Pharmaceuticals, Inc.
California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Tallikut Pharmaceuticals, Inc. is a private pharmaceutical company based in California, United States. Its lead drug candidate was Atreleuton (VIA-2291), a small molecule inhibitor of the enzyme five-lipoxygenase (5-LOX), developed for cardiovascular and inflammatory indications such as carotid stenosis and previously acute coronary syndrome. The most advanced clinical trial reached Phase II but the program has since been discontinued. There are no publicly disclosed active pipeline programs or recent clinical results as of early-2025.
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
Beyond the preview
Go deeper on Tallikut Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tallikut Pharmaceuticals, Inc..